The Food and Drug Administration issued warning letters to 30 telehealth companies, stepping up enforcement against compounded GLP‑1 weight-loss drugs being marketed as cheaper alternatives to FDA-approved treatments amid soaring demand.
The letters, sent Feb. 20 and made public this week, cite false or misleading claims about compounded glucagon-like peptide‑1 medications on company websites. Regulators said the companies promoted these products as substitutes for FDA-approved therapies used to treat diabetes and obesity, even though compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before reaching patients.
The warning letters highlight several types of violations. In some cases, companies suggested their products contained the same active ingredients as widely prescribed GLP-1 drugs such as semaglutide or tirzepatide, implying equivalence to approved medications. Regulators also flagged promotions that obscured the drug's source, including marketing under a telehealth company's brand or trademark in ways that could make consumers think the company manufactured the product. Some materials included unsupported claims about safety or effectiveness, which the FDA said can mislead patients.
Many companies have attempted to skirt the rules by citing a "personalization" strategy, arguing that individually tailored doses of compounded GLP‑1 drugs make the products legal. Earlier this year, telehealth company Hims & Hers Health attempted to sell a compounded pill version of Novo Nordisk's Wegovy for as little as $49 per month, but backed down after the FDA warned it could face enforcement action.
In early February, the FDA signaled it would take "decisive steps" to restrict active ingredients used in non‑FDA‑approved compounded GLP‑1 drugs being mass-marketed as alternatives to approved therapies. The agency emphasized that such products cannot be marketed as equivalent to FDA-approved medications and warned that failure to address violations could lead to legal action, including seizure or injunction.
Companies that received letters have 15 working days to respond and outline how they will correct the violations. The enforcement follows earlier warnings from FDA leadership. In a February post on X, Commissioner Marty Makary said the agency would take "swift action against companies mass-marketing illegal copycat drugs" promoted as alternatives to FDA-approved medications.
Compounded drugs can legally be prepared by pharmacists or physicians to meet the needs of individual patients, such as during shortages or when a patient requires a customized formulation. Regulators emphasize, however, that they cannot be mass-produced or marketed as replacements for approved therapies.
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.